This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.
Signed informed consent
Relapsed or refractory solid tumor after at least one prior course of therapy.
Hodgkin lymphoma or non-Hodgkin lymphoma are not permitted.
Patients with CNS malignancy or asymptomatic CNS metastases may be enrolled, provided all of the following criteria are met.
Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of study treatment
Women of childbearing potential must have a negative serum pregnancy test result within 21 days prior to initiation of study treatment.
Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.
Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.